Darolutamide Takes Root With New Prostate Cancer Benchmark

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

Read the full article here

Related Articles